Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder
Record ID 32002000020
To summarise the available evidence on transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladders.
Authors' recomendations: - The oxybutynin patch is a transdermal delivery system, which releases the drug oxybutynin through the skin for the management of overactive bladder. - Limited evidence suggests that transdermal delivery of oxybutynin over a short period of time may have efficacy comparable to oral oxybutynin. - Recent phase II and III clinical trials supported by the manufacturer suggest a potentially reduced incidence of dry mouth compared to oral oxybutynin. Itching, however, is present in 18% of patients, and the patients' withdrawal rate due to adverse events after 12 weeks is significant (10%). - More studies are required to determine the long-term efficacy and safety of the oxybutynin patch for overactive bladder. - A New Drug Application for transdermal oxybutynin (Oxytrol(R)) is currently under review at the U.S. Food and Drug Administration. As of October 2001, the oxybutynin patch has not been approved in Canada.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Mandelic Acids
- Urinary Bladder
- Urination Disorders
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.